๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 44 Guangzhou 29 Shanghai 25 Tianjin 22 Hangzhou 20
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing44 Guangzhou29 Shanghai25 Tianjin22 Hangzhou20
All 57 locations
Target enrolment
to

Trials with a site in Hangzhou

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938Multiple Myeloma
Hoffmann-La Roche
Phase 3
380
Guangzhou, Nanjing, Qingdao, Kunming, Hangzhou, Jinan, Nanning, Shanghai
2026-06-23
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou
2026-02-04
Recruiting
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06644118Multiple Myeloma
Zhejiang University
Phase 1
58
Beijing, Xiโ€™an, Hangzhou
2024-10-23
Active, closed
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
NCT06566547Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
116
Hangzhou
2024-08-26
Recruiting
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
NCT06520176Multiple Myeloma, Hematopoietic Stem Cell Mobilization
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08
Recruiting
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06464991Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
240
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Recruiting
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
NCT06235229Multiple Myeloma
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
NCT06463717Multiple Myeloma, Minimal Residual Disease
DrugASCT
First Affiliated Hospital of Zhejiang University
Observational
210
Hangzhou
2023-12-01
Recruiting
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06057402Multiple Myeloma
Pfizer
Phase 4
80
Beijing, Guangzhou, Jinan, Hangzhou
2023-10-03
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
213
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Recruiting
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05722405Multiple Myeloma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Hangzhou
2022-07-01
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Recruiting
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
NCT04662294Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma
Zhejiang University
Phase EARLY_PHASE1
108
Hangzhou
2021-11-18
Active, closed
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
587
Beijing, Changchun, Changshashi, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2021-10-14
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
GlaxoSmithKline
Phase 3
302
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Jiangsu, Nanchang, Shenyang
2020-10-01
Active, closed
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210Multiple Myeloma
GlaxoSmithKline
Phase 3
325
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Tianjin
2020-04-02
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Hangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Hangzhou?

12 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hangzhou), 20 studies
PhaseStudiesRecruitingShare
Phase 312560%
Phase 43315%
Observational115%
Phase 1115%
Phase 1/2115%
Phase 2105%
Phase EARLY_PHASE1115%

Most active sponsors

Lead sponsors with the most studies (Hangzhou)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC62
GlaxoSmithKline41
Zhejiang University22
First Affiliated Hospital of Zhejiang University11
Genrix (Shanghai) Biopharmaceutical Co., Ltd.10
Gracell Biotechnologies (Shanghai) Co., Ltd.11
Hoffmann-La Roche11
Nanjing IASO Biotechnology Co., Ltd.11
Pfizer11
Second Affiliated Hospital, Zhejiang University, School of Medicine11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.